Sarepta Therapeutics (SRPT) Posts Slightly Smaller Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments
May 5, 2016 7:01 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc.(NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months ended March 31, 2016, and provided an update of recent corporate developments.
The Peripheral and Central Nervous System Advisory Committee met last week to review eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping, and we await our May 26 PDUFA date, said Edward Kaye, M.D., Sareptas interim chief executive officer and chief medical officer. Following the FDAs decision, we plan to provide a clinical and corporate update.
... More